Tech Executive Battles Early-Onset Alzheimer's with New US Biotech Startup
Ofer Shina, who carries a genetic mutation linked to early-onset Alzheimer's, co-founded a biotech startup backed by a $2.74 million grant to develop life-saving treatments.

Ofer Shina, the 38-year-old son-in-law of veteran journalist Shlomi Eldar, is leading an unprecedented personal race against a genetic disease that claimed his father's life and threatens his own future. Shina discovered that he carries the hereditary PSEN1 gene mutation, which is linked to early-onset Alzheimer's disease. To combat the condition, he co-founded an American biotechnology firm that recently secured a $2.74 million grant from the Michael J. Fox Foundation to advance treatments for neurodegenerative disorders.
Speaking to the press, Shina recounted how the devastating illness struck multiple members of his family, often manifesting as early as their 40s. His father passed away from the condition when Shina was only six years old. When planning his own family years later, Shina underwent genetic screening and confirmed he was a carrier, though testing verified that his son is entirely free of the mutation.
Building a Biotech Startup from Scratch
Behind the personal crusade lies an extraordinary entrepreneurial endeavor. With 13 years of experience as a high-tech product manager and no formal background in biology, Shina began studying scientific literature every morning. According to media reports, he examined more than 200 therapeutic approaches and thousands of research papers before discovering the breakthrough work of Prof. Varda Shoshan-Barmatz at Ben-Gurion University of the Negev.
The path to establishing a collaboration was arduous. Shoshan-Barmatz initially doubted Shina, who approached her without financial backing or institutional investors, while Dr. Galit Mazoz-Perlmuter of BGN Technologies deflected his inquiries for an entire year before agreeing to talk. Persistence ultimately paid off with the launch of Extozis, an American company developing a therapeutic candidate based on the Israeli research.
Clinical Trials and Commercial Timeline
In June, the Michael J. Fox Foundation awarded Extozis a $2.74 million grant to advance its leading drug candidate toward human clinical trials, starting with Parkinson's disease. Shina aims to initiate human testing within a year and a half, though commercial approval remains a distant horizon.
Company CEO Erin Henderson estimated that even under an optimistic scenario, obtaining full regulatory approval will take approximately six years, acknowledging the sobering reality that time may run short for Shina himself. Explaining the decision to base the company in the USA near regulatory authorities, Shina emphasized: "We need to advance as quickly as possible, hopefully in time for me, but also for all the other patients who truly need this treatment."





